

Attorney Docket No.: PENN-0065
Inventors: Wolfe and Fraser
Serial No.: 08/393,066
Filing Date: February 23, 1995
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A method of stably expressing a selected DNA sequence in the central nervous system of a mammal comprising administering to peripheral neuron cells of a the mammal a neurotropic viral vector which infects cells of the central nervous system of the mammal, said vector containing a selected DNA sequence operatively linked to a selected promoter so that said selected DNA sequence is stably expressed for at least four months by infected central nervous system cells.

Claim 2 (original): The method of claim 1 wherein the selected promoter is the LAT promoter.

Claim 3 (original): The method of claim 1 wherein the selected DNA sequence encodes β -glucuronidase.

Claim 4 (original): The method of claim 1 wherein the selected DNA sequence encodes tyrosine hydroxylase.

Claim 5 (original): The method of claim 1 wherein the viral vector comprises an HSV vector.

Claim 6 (original): The method of claim 5 wherein the HSV vector comprises an HSV-1 strain.

Attorney Docket No.: **PENN-0065**
Inventors: **Wolfe and Fraser**
Serial No.: **08/393,066**
Filing Date: **February 23, 1995**
Page 3

Claim 7 (original): The method of claim 6 wherein the HSV-1 strain comprises strain 17.

Claim 8. (currently amended): A method of stably expressing β -glucuronidase in the brain of a mammal comprising administering to peripheral neuron cells of a ~~the~~ mammal a neurotropic viral vector which infects cells of the brain of the mammal, said vector being an HSV-1 vector containing a DNA sequence encoding β -glucuronidase operatively linked to a LAT promoter, so that the infected brain cells stably express β -glucuronidase.

Claim 9 (original): The method of claim 8 wherein the HSV-1 vector comprises HSV-1 strain 17.